Cost of Biosimilar Product Development

The contract aims to support the development of a valuation model to evaluate the strategic decision of bringing a biosimilar and interchangeable biological product to market, focusing on the financial and operational costs associated with such an endeavor. This initiative is being led by the Office of the Assistant Secretary for Planning and Evaluation within the U.S. Department of Health and Human Services, with the North American Industry Classification System code 921190 indicating its alignment with other miscellaneous governmental functions related to public health policy and economic analysis. The project seeks to generate insights that inform public health planning and policy decisions related to biosimilar market entry, potentially impacting pricing, competition, and patient access to biologic therapies. Sonal Parasrampuria serves as the program point of contact for technical and project-related inquiries, while Lydina Battle is designated as the contracting officer responsible for procurement and contractual matters. The opportunity was posted on May 25, 2026, under a forecast classification, suggesting it is a preliminary notice of an upcoming procurement rather than a current solicitation. There is no specific set-aside designation or place of performance location identified, and the office address details are incomplete, indicating this is an early-stage planning notice intended to provide industry stakeholders with advance visibility into a future funding opportunity. The full opportunity can be accessed through the provided link on the Office of Small and Disadvantaged Business Utilization website.